Characterization of the anti-solvent batch, plug flow and MSMPR crystallization of benzoic acid

Abstract Continuous operation allows process conditions that are not attainable within batch crystallizers to be utilized. This in turn allows for product crystal attributes that are not possible in the equivalent batch crystallizations to be produced. In this study, the product crystal size distributions attainable from the anti-solvent crystallization of benzoic acid in plug flow, MSMPR and the equivalent fed batch and batch reverse addition crystallizations, were characterized. It was found that the continuous plug flow and MSMPR crystallizers were able to access crystal size distributions that are both smaller and larger than could be produced via the equivalent batch crystallizations, in addition to providing huge increases in productivity. In-situ process analytical techniques (FBRM, ATR-FTIR) were employed to characterize each of these processes, including a calibration-free ATR-FTIR technique. Furthermore, a novel intermittent pneumatic MSMPR withdrawal method, which negated clogging/fouling of transfer lines, is demonstrated. It is hoped that the use of such techniques may facilitate the uptake of continuous processes in pharmaceutical crystallization where limitations on development time and concerns about slurry transport are perceived to be barriers to the implementation of this technology.

[1]  Gerry Steele,et al.  Continuous Crystallization of Pharmaceuticals Using a Continuous Oscillatory Baffled Crystallizer , 2009 .

[2]  Marco Mazzotti,et al.  Continuous precipitation of L‐asparagine monohydrate in a micromixer: Estimation of nucleation and growth kinetics , 2011 .

[3]  Marco Mazzotti,et al.  Experimental characterization and multi-scale modeling of mixing in static mixers , 2008 .

[4]  E. L. Paul,et al.  Investigation of impinging‐jet crystallization with a calcium oxalate model system , 2003 .

[5]  C. Lipinski.  Poor aqueous solubility-an industry wide problem in drug discovery , 2002 .

[6]  San Kiang,et al.  Can pharmaceutical process development become high tech , 2006 .

[7]  B. Glennon,et al.  In-situ monitoring and characterization of plug flow crystallizers , 2012 .

[8]  Marco Mazzotti,et al.  Experimental characterization and multi-scale modeling of mixing in static mixers. Part 2. Effect of viscosity and scale-up , 2009 .

[9]  B. Glennon,et al.  The role of meso-mixing in anti-solvent crystallization processes , 2011 .

[10]  A. Randolph,et al.  Theory of Particulate Processes: Analysis and Techniques of Continuous Crystallization , 1971 .

[11]  Dimitrios I. Gerogiorgis,et al.  Economic Analysis of Integrated Continuous and Batch Pharmaceutical Manufacturing: A Case Study , 2011 .

[12]  B. Glennon,et al.  Supersaturation tracking for the development, optimization and control of crystallization processes , 2010 .

[13]  S. Y. Wong,et al.  Development of Continuous Crystallization Processes Using a Single-Stage Mixed-Suspension, Mixed-Product Removal Crystallizer with Recycle , 2012 .

[14]  Allan S. Myerson,et al.  Crystallization of Cyclosporine in a Multistage Continuous MSMPR Crystallizer , 2011 .

[15]  K. Plumb,et al.  Continuous Processing in the Pharmaceutical Industry: Changing the Mind Set , 2005 .

[16]  J. Nývlt,et al.  The Kinetics of industrial crystallization , 1984 .

[17]  B. Glennon,et al.  The Effect of Mixing on the Metastable Zone Width and Nucleation Kinetics in the Anti-Solvent Crystallization of Benzoic Acid , 2007 .

[18]  R. Müller,et al.  Nanocrystals of Poorly Soluble Drugs for Oral Administration , 2003 .

[19]  Ronald W. Rousseau,et al.  Batch and Tubular-Batch Crystallization of Paracetamol: Crystal Size Distribution and Polymorph Formation , 2006 .

[20]  Åke C. Rasmuson,et al.  Reaction crystallization kinetics of benzoic acid , 2001 .

[21]  Stefan Radl,et al.  Continuously Seeded, Continuously Operated Tubular Crystallizer for the Production of Active Pharmaceutical Ingredients , 2010 .